Research ExplorerPublicationsImmuno-targeting the multifunctional CD38 using nanobody

Immuno-targeting the multifunctional CD38 using nanobody

Standard

Immuno-targeting the multifunctional CD38 using nanobody. / Li, Ting; Qi, Shali; Unger, Mandy; Hou, Yun Nan; Deng, Qi Wen; Liu, Jun; Lam, Connie M C; Wang, Xian Wang; Xin, Du; Zhang, Peng; Nolte, Friedrich; Hao, Quan; Zhang, Hongmin; Lee, Hon Cheung; Zhao, Yong Juan.

In: SCI REP-UK, Vol. 6, 02.06.2016, p. 27055.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Li, T, Qi, S, Unger, M, Hou, YN, Deng, QW, Liu, J, Lam, CMC, Wang, XW, Xin, D, Zhang, P, Nolte, F, Hao, Q, Zhang, H, Lee, HC & Zhao, YJ 2016, 'Immuno-targeting the multifunctional CD38 using nanobody', SCI REP-UK, vol. 6, pp. 27055. https://doi.org/10.1038/srep27055

APA

Li, T., Qi, S., Unger, M., Hou, Y. N., Deng, Q. W., Liu, J., Lam, C. M. C., Wang, X. W., Xin, D., Zhang, P., Nolte, F., Hao, Q., Zhang, H., Lee, H. C., & Zhao, Y. J. (2016). Immuno-targeting the multifunctional CD38 using nanobody. SCI REP-UK, 6, 27055. https://doi.org/10.1038/srep27055

Vancouver

Li T, Qi S, Unger M, Hou YN, Deng QW, Liu J et al. Immuno-targeting the multifunctional CD38 using nanobody. SCI REP-UK. 2016 Jun 2;6:27055. https://doi.org/10.1038/srep27055

Bibtex

@article{659f3eb456a04699966be587f8d1e094,
title = "Immuno-targeting the multifunctional CD38 using nanobody",
abstract = "CD38, as a cell surface antigen is highly expressed in several hematologic malignancies including multiple myeloma (MM) and has been proven to be a good target for immunotherapy of the disease. CD38 is also a signaling enzyme responsible for the metabolism of two novel calcium messenger molecules. To be able to target this multifunctional protein, we generated a series of nanobodies against CD38 with high affinities. Crystal structures of the complexes of CD38 with the nanobodies were solved, identifying three separate epitopes on the carboxyl domain. Chromobodies, engineered by tagging the nanobody with fluorescence proteins, provide fast, simple and versatile tools for quantifying CD38 expression. Results confirmed that CD38 was highly expressed in malignant MM cells compared with normal white blood cells. The immunotoxin constructed by splicing the nanobody with a bacterial toxin, PE38 shows highly selective cytotoxicity against patient-derived MM cells as well as the cell lines, with half maximal effective concentration reaching as low as 10(-11) molar. The effectiveness of the immunotoxin can be further increased by stimulating CD38 expression using retinoid acid. These results set the stage for the development of clinical therapeutics as well as diagnostic screening for myeloma.",
keywords = "Journal Article",
author = "Ting Li and Shali Qi and Mandy Unger and Hou, {Yun Nan} and Deng, {Qi Wen} and Jun Liu and Lam, {Connie M C} and Wang, {Xian Wang} and Du Xin and Peng Zhang and Friedrich Nolte and Quan Hao and Hongmin Zhang and Lee, {Hon Cheung} and Zhao, {Yong Juan}",
year = "2016",
month = jun,
day = "2",
doi = "10.1038/srep27055",
language = "English",
volume = "6",
pages = "27055",
journal = "SCI REP-UK",
issn = "2045-2322",
publisher = "NATURE PUBLISHING GROUP",

}

RIS

TY - JOUR

T1 - Immuno-targeting the multifunctional CD38 using nanobody

AU - Li, Ting

AU - Qi, Shali

AU - Unger, Mandy

AU - Hou, Yun Nan

AU - Deng, Qi Wen

AU - Liu, Jun

AU - Lam, Connie M C

AU - Wang, Xian Wang

AU - Xin, Du

AU - Zhang, Peng

AU - Nolte, Friedrich

AU - Hao, Quan

AU - Zhang, Hongmin

AU - Lee, Hon Cheung

AU - Zhao, Yong Juan

PY - 2016/6/2

Y1 - 2016/6/2

N2 - CD38, as a cell surface antigen is highly expressed in several hematologic malignancies including multiple myeloma (MM) and has been proven to be a good target for immunotherapy of the disease. CD38 is also a signaling enzyme responsible for the metabolism of two novel calcium messenger molecules. To be able to target this multifunctional protein, we generated a series of nanobodies against CD38 with high affinities. Crystal structures of the complexes of CD38 with the nanobodies were solved, identifying three separate epitopes on the carboxyl domain. Chromobodies, engineered by tagging the nanobody with fluorescence proteins, provide fast, simple and versatile tools for quantifying CD38 expression. Results confirmed that CD38 was highly expressed in malignant MM cells compared with normal white blood cells. The immunotoxin constructed by splicing the nanobody with a bacterial toxin, PE38 shows highly selective cytotoxicity against patient-derived MM cells as well as the cell lines, with half maximal effective concentration reaching as low as 10(-11) molar. The effectiveness of the immunotoxin can be further increased by stimulating CD38 expression using retinoid acid. These results set the stage for the development of clinical therapeutics as well as diagnostic screening for myeloma.

AB - CD38, as a cell surface antigen is highly expressed in several hematologic malignancies including multiple myeloma (MM) and has been proven to be a good target for immunotherapy of the disease. CD38 is also a signaling enzyme responsible for the metabolism of two novel calcium messenger molecules. To be able to target this multifunctional protein, we generated a series of nanobodies against CD38 with high affinities. Crystal structures of the complexes of CD38 with the nanobodies were solved, identifying three separate epitopes on the carboxyl domain. Chromobodies, engineered by tagging the nanobody with fluorescence proteins, provide fast, simple and versatile tools for quantifying CD38 expression. Results confirmed that CD38 was highly expressed in malignant MM cells compared with normal white blood cells. The immunotoxin constructed by splicing the nanobody with a bacterial toxin, PE38 shows highly selective cytotoxicity against patient-derived MM cells as well as the cell lines, with half maximal effective concentration reaching as low as 10(-11) molar. The effectiveness of the immunotoxin can be further increased by stimulating CD38 expression using retinoid acid. These results set the stage for the development of clinical therapeutics as well as diagnostic screening for myeloma.

KW - Journal Article

U2 - 10.1038/srep27055

DO - 10.1038/srep27055

M3 - SCORING: Journal article

C2 - 27251573

VL - 6

SP - 27055

JO - SCI REP-UK

JF - SCI REP-UK

SN - 2045-2322

ER -